• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.

作者信息

Kohn Milena, Delord Marc, Chbat Maureen, Guemriche Amina, Merabet Fatiha, Roupie Anne-Laure, Lombion Naelle, Farhat Hassan, Longval Thomas, Cabannes-Hamy Aurélie, Lambert Juliette, Marque-Juillet Stéphanie, Raggueneau Victoria, Osman Jennifer, Spentchian Marc, Rigaudeau Sophie, Rousselot Philippe, Besson Caroline

机构信息

Service d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, 78150.

DRCI, Centre Hospitalier de Versailles, Le Chesnay, 78150.

出版信息

Haematologica. 2022 Jun 1;107(6):1454-1459. doi: 10.3324/haematol.2021.280026.

DOI:10.3324/haematol.2021.280026
PMID:34788987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9152953/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7664/9152953/764550542be8/1071454.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7664/9152953/b24b72e843d6/1071454.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7664/9152953/764550542be8/1071454.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7664/9152953/b24b72e843d6/1071454.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7664/9152953/764550542be8/1071454.fig2.jpg

相似文献

1
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.对于淋巴瘤或慢性淋巴细胞白血病患者，第三剂抗SARS-CoV-2 mRNA疫苗无法克服抗CD20疗法和/或低免疫球蛋白水平的不良影响。
Haematologica. 2022 Jun 1;107(6):1454-1459. doi: 10.3324/haematol.2021.280026.
2
Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.通过抗CD20单克隆抗体利妥昔单抗治疗选择B细胞慢性淋巴细胞白血病细胞变体。
Exp Hematol. 2001 Dec;29(12):1410-6. doi: 10.1016/s0301-472x(01)00753-6.
3
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.利妥昔单抗对慢性淋巴细胞白血病患者CD20的短暂下调作用
Blood. 2003 Nov 15;102(10):3514-20. doi: 10.1182/blood-2003-01-0055. Epub 2003 Jul 31.
4
What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?新型抗CD20抗体在慢性淋巴细胞白血病治疗中的现状如何，它们是否会让利妥昔单抗黯然失色？
Expert Rev Hematol. 2015 Dec;8(6):733-42. doi: 10.1586/17474086.2015.1087844. Epub 2015 Sep 14.
5
HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.组蛋白去乙酰化酶 6 抑制上调 CD20 水平并增强抗 CD20 单克隆抗体的疗效。
Blood. 2017 Oct 5;130(14):1628-1638. doi: 10.1182/blood-2016-08-736066. Epub 2017 Aug 22.
6
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.含抗CD20抗体方案治疗复发或难治性慢性淋巴细胞白血病、弥漫性大B细胞淋巴瘤或滤泡性淋巴瘤患者的循证综述
Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):508-518.e14. doi: 10.1016/j.clml.2018.05.009. Epub 2018 May 23.
7
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.抗CD20抗体（IDEC-C2B8，利妥昔单抗）在体外增强细胞毒性药物对肿瘤淋巴细胞的疗效：细胞因子、补体和半胱天冬酶的作用
Haematologica. 2002 Jan;87(1):33-43.
8
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
9
Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.利妥昔单抗治疗后出现 CD20 阴性表型改变的 10 例 B 细胞非霍奇金淋巴瘤患者的随访数据。
Am J Surg Pathol. 2013 Apr;37(4):563-70. doi: 10.1097/PAS.0b013e3182759008.
10
Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.富含嘌呤的盒式结构-1介导的CD20表达降低改变了利妥昔单抗诱导的慢性淋巴细胞白血病B细胞裂解。
Cancer Res. 2008 Sep 15;68(18):7512-9. doi: 10.1158/0008-5472.CAN-07-6446.

引用本文的文献

1
Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病的疫苗挑战：对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）免疫接种对慢性淋巴细胞白血病患者疗效的全面探索
Ann Hematol. 2024 Dec;103(12):4971-4980. doi: 10.1007/s00277-024-05869-8. Epub 2024 Jul 15.
2
Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin's Lymphoma: A Single-Center Cohort Study.COVID-19 mRNA 疫苗加强针的初步疗效及随后在 B 细胞非霍奇金淋巴瘤患者中奥密克戎变异株突破性感染的研究：一项单中心队列研究。
Viruses. 2024 Feb 21;16(3):328. doi: 10.3390/v16030328.
3

本文引用的文献

1
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.抗CD20单克隆抗体对B细胞非霍奇金淋巴瘤患者接种BNT162b2疫苗血清学反应的影响
Leukemia. 2022 Feb;36(2):588-590. doi: 10.1038/s41375-021-01418-8. Epub 2021 Sep 20.
2
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.BNT162b2 mRNA COVID-19 疫苗在 B 细胞非霍奇金淋巴瘤患者中的疗效。
Blood Adv. 2021 Aug 24;5(16):3053-3061. doi: 10.1182/bloodadvances.2021005094.
3
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies.
血液系统恶性肿瘤患者新冠病毒加强疫苗的血清学反应及预测因素
J Clin Med. 2023 Aug 30;12(17):5647. doi: 10.3390/jcm12175647.
4
Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies.mRNA 疫苗加强针在血液系统恶性肿瘤患者中的效果。
Cancer Med. 2023 Aug;12(16):16881-16888. doi: 10.1002/cam4.6314. Epub 2023 Jul 6.
5
Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms.体液免疫对基于 mRNA 的 COVID-19 疫苗的反应和第三剂对成熟 T 细胞和 NK 细胞肿瘤患者的增强效应。
Ann Hematol. 2023 Apr;102(4):819-827. doi: 10.1007/s00277-023-05142-4. Epub 2023 Mar 2.
6
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.免疫原性和与血液恶性肿瘤患者在接种 SARS-CoV-2 疫苗和加强针后免疫反应受损相关的风险：一项更新的荟萃分析。
Blood Cancer J. 2022 Dec 23;12(12):173. doi: 10.1038/s41408-022-00776-5.
7
Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine.慢性淋巴细胞白血病患者对BNT162b2疫苗无反应的风险非常高。
Vaccines (Basel). 2022 Jul 21;10(7):1162. doi: 10.3390/vaccines10071162.
8
COVID-19 in patients with hematologic malignancy.血液恶性肿瘤患者中的 COVID-19 感染。
Blood. 2022 Jul 21;140(3):236-252. doi: 10.1182/blood.2021012251.
9
Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.关于慢性淋巴细胞白血病中 SARS-CoV-2 疫苗接种的当前观点。
Hematol Oncol. 2022 Aug;40(3):313-319. doi: 10.1002/hon.2990. Epub 2022 Mar 23.
10
Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.mRNA 新冠疫苗在骨髓恶性肿瘤患者中的体液免疫反应。
Br J Haematol. 2022 Jun;197(6):691-696. doi: 10.1111/bjh.18138. Epub 2022 Mar 14.
移植受者中第三剂mRNA-1273疫苗的随机试验。
N Engl J Med. 2021 Sep 23;385(13):1244-1246. doi: 10.1056/NEJMc2111462. Epub 2021 Aug 11.
4
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.接受免疫抑制治疗的患者对 SARS-CoV-2 疫苗接种的体液和 T 细胞反应。
Ann Rheum Dis. 2021 Oct;80(10):1322-1329. doi: 10.1136/annrheumdis-2021-220626. Epub 2021 Aug 6.
5
Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab.接受利妥昔单抗治疗的类风湿关节炎患者接种新型冠状病毒疫苗后特异性T细胞反应的存在情况。
Immunol Res. 2021 Aug;69(4):309-311. doi: 10.1007/s12026-021-09212-5. Epub 2021 Jul 29.
6
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.淋巴瘤患者在接受抗 CD2O 抗体治疗后的 12 个月内，体液血清学对 BNT162b2 疫苗的反应被消除。
Haematologica. 2022 Mar 1;107(3):715-720. doi: 10.3324/haematol.2021.279216.
7
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b mRNA COVID-19 疫苗在慢性淋巴细胞白血病患者中的安全性和有效性。
Haematologica. 2022 Mar 1;107(3):625-634. doi: 10.3324/haematol.2021.279196.
8
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.在接受利妥昔单抗治疗的患者中接种 SARS-CoV-2 疫苗：B 细胞在 T 细胞介导的免疫存在下促进体液免疫反应。
Ann Rheum Dis. 2021 Oct;80(10):1345-1350. doi: 10.1136/annrheumdis-2021-220781. Epub 2021 Jul 20.
9
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者接种三剂mRNA新冠疫苗
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
10
Occurrence of severe COVID-19 in vaccinated transplant patients.接种疫苗的移植患者中出现重症 COVID-19 情况。
Kidney Int. 2021 Aug;100(2):477-479. doi: 10.1016/j.kint.2021.05.011. Epub 2021 May 23.